Navigation Links
Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
Date:11/27/2007

se of gastrointestinal origin (gastroesophageal, pancreatic, and colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly cytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibody alters cellular signaling required for cell survival. RAV12 is highly efficacious in human colon, gastric, and pancreatic tumor xenograft models in vivo and has been found to be well tolerated in repeat dose primate toxicology studies.

About GI Cancers

Adenocarcinomas are malignant tumors of the epithelial cells that line glands or viscera. They typically spread by way of the circulatory or lymphatic systems and are poorly treated after metastatic spread. More than 90 percent of colon, stomach and pancreatic tumor specimens express the RAV12 defined antigen, RAAG12. Adenocarcinomas arising elsewhere, such as breast, endometrial, ovarian, lung and prostate, display the antigen at lower frequency.

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrat
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , Mar. 05, 2015 Research and ... the addition of the "Global Pharma US ... Cost Optimization Plays Major Role In Shaping Up ... to their offering. Strategy Diversification ... in healthy Cash position- Will accelerate Next wave ...
(Date:3/5/2015)... N.J. , March 5, 2015  ContraVir Pharmaceuticals, ... focused on the development and commercialization of targeted antiviral ... 27 th Annual ROTH Conference, to be held ... James Sapirstein , Chief ... business during his live presentation and will be available ...
(Date:3/5/2015)... March 5, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, announced today that Atlanta ... rehabilitation hospitals for spinal cord injury and brain injury, ... of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients ... (SCI). The Phase 1/2a trial follows ...
Breaking Medicine Technology:Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 2Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 3ContraVir to Present at 27th Annual ROTH Conference 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4
... , AUSTIN, Texas, Sept. 14 WillWalk, ... forefront of ending Paralysis. WillWalk will raise $3 million to help fund ... Injury (SCI). , , The money raised will fund ... cells being used are a non-controversial adult stem cell from umbilical cord ...
... , SAN DIEGO, Sept. 13 NexBio, Inc. ... against H1N1 influenza and NAI-resistant influenza at the 2009 Interscience ... September 13, 2009, in San Francisco, CA. The work ... Disease Control and Prevention (CDC), University of Hong Kong, and ...
Cached Medicine Technology:Paralyzed Artist Launches WillWalk Foundation to Cure Paralysis with Breakthrough Stem Cell Research 2NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009 2NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009 3
(Date:3/5/2015)... In honor of National Drug Facts ... drug and alcohol abuse in schools and communities across ... with information on some of the dangers and statistics ... National Institute on Drug Abuse, this annual promotion of ... the illusions that teens and young adults get from ...
(Date:3/5/2015)... 05, 2015 Califia Farms , ... the natural products coffee drinks category[1], today unveils its ... West in Anaheim, Calif. Concentrated Cold Brew (CCB) ... Café, which democratizes the next wave of the coffee-taste ... need to become their own baristas. , Califia ...
(Date:3/5/2015)... York, NY (PRWEB) March 05, 2015 ... orthopedic Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named by ... the New York Metro area. Dr. Glashow has been ... its authoritative guide to the top specialty care doctors ... , The prestigious Castle Connolly program, which carefully screens ...
(Date:3/5/2015)... Nutrition Leaders, a premier purveyor of health, diet, ... Millennium 500 Creatine to its customers. Available from the ... creatine supplement that has been micronized to more quickly ... overall strength gains in users. , Creatine is a ... source in the body and helps fuel muscle contractions ...
(Date:3/5/2015)... 05, 2015 Wimbledon Health Partners ... vascular, echocardiogram and NCV testing, announced the ... Chief Medical Officer. Dr. Artel will be responsible for ... the WimbledonMED program and the continued growth and support ... working with Wimbledon Health Partners as a consulting physician ...
Breaking Medicine News(10 mins):Health News:A Forever Recovery Issues New Tips for Sobriety for National Drug Facts Week 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Nutrition Leaders Offers Reformulated Millennium 500 German Grade Creatine 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3
... in a Queen,s University-led study do not have an influenza ... tested. In addition, key players were not involved in developing ... not good enough just to have a plan, you have ... will work in an emergency," says Dick Zoutman, Queen,s professor ...
... , AKRON, Ohio , Feb. 10 ... is launching its first bachelor,s degree programs in its 40-year ... Administration with a Business Management concentration Bachelor of Science ... Information Management Bachelor of Science – Technology Management with ...
... or GAD, have abnormalities in the way their brain unconsciously ... School of Medicine study, and the study authors say the ... our understanding of how emotion is regulated in everyday life. ... American Journal of Psychiatry. According to the National ...
... ... celiac disease, one of the most common and under-diagnosed autoimmune diseases, it,s symptoms, and how ... a year, one being day-time Emmy Award winner, Elisabeth Hasselbeck of ABC’s “The View”. ... (PRWEB) February 11, 2010 -- ...
... removal of tumors, study found , WEDNESDAY, Feb. 10 (HealthDay ... levels of spiritual thinking and feeling in patients, a finding ... and the physical makeup of the mind, researchers say. , ... Neuron , are based on research in patients who had ...
... , , PUYALLUP, Wash. , ... IT stimulus and the American Recovery and Reinvestment Act ... comprehensive digital imaging and data management integration project with ... paying dividends for MINW patients even after the completion ...
Cached Medicine News:Health News:Akron Institute of Herzing University Launches Its First Bachelor's Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT 2Health News:Akron Institute of Herzing University Launches Its First Bachelor's Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT 3Health News:People with anxiety disorder less able to regulate response to negative emotions, study shows 2Health News:People with anxiety disorder less able to regulate response to negative emotions, study shows 3Health News:Multi-Award Winning Author Tina Turbin Interviews Special Guest Dr. Peter H.R. Green, M.D. On The Thrive in Balance Radio Show 2Health News:Physical Changes in Brain Linked to Altered Spirituality 2Health News:Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements 2Health News:Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements 3
The Mini Vidas is a compact version of the Vidas system with a built-in computer, keyboard and printer. Two independent sections each accept six tests and can process up to 12 samples simultaneously....
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: